C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H2 2018

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H2 2018


  • Products Id :- GMDHC1721TDB
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)-Pipeline Review, H2 2018

Summary

According to the recently published report 'C-X-C Chemokine Receptor Type 1-Pipeline Review, H2 2018'; C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)-C-X-C Chemokine Receptor Type 1 is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity.

The report 'C-X-C Chemokine Receptor Type 1-Pipeline Review, H2 2018' outlays comprehensive information on the C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Respiratory, Central Nervous System, Dermatology and Metabolic Disorders which include indications Autoimmune Disorders, Bronchopulmonary Dysplasia, Chronic Obstructive Pulmonary Disease (COPD), Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammation, Inflammatory Pain, Liver Transplant Rejection, Lung Cancer, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Pancreatic Islet Transplant Rejection, Post-Operative Pain, Pulmonary Inflammation and Type 1 Diabetes (Juvenile Diabetes).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)

- The report reviews C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics and enlists all their major and minor projects

- The report assesses C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)-Overview

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)-Companies Involved in Therapeutics Development

Dompe Farmaceutici SpA

Eli Lilly and Co

Merck & Co Inc

Syntrix Biosystems Inc

Vaccibody AS

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)-Drug Profiles

DF-2755A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ladarixin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3041658-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

navarixin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-G31P-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reparixin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SX-517-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SX-576-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SX-682-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Melanoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)-Dormant Products

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)-Discontinued Products

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)-Product Development Milestones

Featured News & Press Releases

Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells

Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer

Oct 01, 2014: Dompe commitment in oncology against cancer stem cells

Sep 25, 2013: Pharmaceutical company Dompe launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation

Jul 10, 2013: Dompe announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true

Dec 06, 2012: Dompe Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium

Oct 23, 2012: Dompe Announces Enrollment Of First Patient In Phase III Trial On Reparixin

Oct 24, 2011: Dompe Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress

Oct 13, 2011: Dompe's Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Dompe Farmaceutici SpA, H2 2018

Pipeline by Eli Lilly and Co, H2 2018

Pipeline by Merck & Co Inc, H2 2018

Pipeline by Syntrix Biosystems Inc, H2 2018

Pipeline by Vaccibody AS, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Dompe Farmaceutici SpA

Eli Lilly and Co

Merck & Co Inc

Syntrix Biosystems Inc

Vaccibody AS

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) Therapeutic Products under Development, Key Players in C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) Therapeutics, C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) Pipeline Overview, C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) Pipeline, C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) Pipeline Assessment

select a license
Single User License
USD 3500 INR 240170
Site License
USD 7000 INR 480340
Corporate User License
USD 10500 INR 720510

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com